Deborah K. Armstrong, M.D.


Co-PI, Developmental Research Program

Co-Investigator, Project 6


University of California

Berkeley, CA.

A.B. (Bacteriology), 1975

George Washington University School of Medicine

Washington, DC.

M.D., 1984

University of Pittsburgh

Pittsburgh, PA.

Resident in Internal Medicine, 1984-1987.

University of Pittsburgh

Pittsburgh, PA.

Chief Resident in Internal Medicine, 1987-1988.

The Johns Hopkins University School of Medicine

Baltimore, MD.

Fellow in Oncology, 1988-1993.

Professional Experience


Instructor in Medicine, Chief Medical Resident, University or Pittsburgh, Department of Internal Medicine


Instructor in Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD


Instructor in Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD


Active Staff, Oncology, The Johns Hopkins Hospital, Baltimore, MD


Principal Investigator, Gynecologic Oncology Group


Assistant Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD


Ovarian Committee, Gynecologic Oncology Group


National Institutes of Health, Office of Research on Women’s Health. Scientific Issues for Women’s Health Research: Cancer Working Group


National Institutes of Health, General Clinical Research Center site visit reviewer (ad hoc)


National Comprehensive Cancer Network, Ovarian Cancer Panel


National Comprehensive Cancer Network, Bone Marrow Transplant Panel


Developmental Therapeutics Committee, Gynecologic Oncology Group


Phase I Committee, Gynecologic Oncology Group


Department of Defense Breast Cancer Research Program Peer Review Panel


Assistant Professor of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, MD

Selected Publications
Arieff AI, Cooper JD, Armstrong DK, Lazarowitz VC: Dementia, renal failure, and brain aluminum. Ann Intern Med 1979;90:741-47.

McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989;111:273-79.

Armstrong DK, Ettinger DS: Current approaches to treatment of hypercalcemia of malignancy. Mod Med 1990;45:226-31.

Armstrong DK, Gordon GB, Hilton J, Colvin OM, Davidson NE: Hepsulfam sensitivity in human breast cancer cell lines: the role of glutathione and glutathione S-transferase in resistance. Cancer Res 1992;52:1416-21.

Armstrong DK, Isaacs JT, Ottaviano YL, Davidson NE: Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. Cancer Res 1992;52:3418-24.

Armstrong DK, Fetting JH, Davidson NE, Gordon GB, Huelskamp AM, Abeloff MD: Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Res Treat 1993;28:277-84.

May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE: Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 in association with suppression of apoptosis. J Biol Chem 1994;43:26865-70.

Armstrong DK, Kaufmann SH, Ottaviano YL, Furuya Y, Buckley JA, Isaacs JT, Davidson NE: Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res 1994;54:5280-83.

Kennedy MJ, Armstrong DK, Huelskamp AM, Ohly K, Clarke BV, Colvin OM, Grochow LB, Chen TL, Davidson NE: Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol 1995;13:1136-43.

McCloskey DE, Armstrong DK, Jackisch C, Davidson NE: Programmed cell death in human breast cancer cells. Recent Prog Horm Res 1996;51:493-508.

O'Reilly S, Fleming GF, Baker S, Walczak JR, Bookman MA, McGuire III WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky ER: A phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a gynecologic oncology group study. J Clin Oncol 1997;15:177-86.

Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, Rowinsky E: Altered formation of topotecan-stabilized topoisomerse I-DNA adducts in human leukemia cells. Blood 1997;89:2098-104.

ten Bokkel Huinink W, Carmichael J, Armstrong DK, Gordon A, Malfetano J: Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin Oncol 1997;24(Suppl 5):19-25.

O'Reilly S, Armstrong DK, Grochow LB: Life threatening myelosuppression in patients with occult renal impairment receiving topotecan. Gynecol Oncol 1997;67:329-30.

Armstrong DK, O'Reilly S: Clinical guidelines for managing topotecan related hematologic toxicity. Oncologist 1998;3:4-10.

Gore SD, Rowinsky EK, Miller CB, Griffin C, Chen TL, Borowitz M, Donehower R, Burks KA, Armstrong DK, Burke PJ, Grever MR, Kaufmann SK: A phase II window study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin Cancer Res 1998;4:2677-89.

Kottke TJ, Blajeski AL, Martins AL, Mesner, Jr. PW, Davidson NE, Earnshaw WC, Armstrong DK, Kaufmann SH: Comparison of paclitaxel, 5-fluoro-2'-deoxyuridine- and epidermal growth factor-induced apoptosis: evidence for EGF-induced anoikis. J Biol Chem 1999;274(22):15927-36.

Hahm HA, Armstrong DK, Chen TL, Grochow LB, Goodman SN, Davidson NE, Kennedy MJ: Phase II study of the alkylating agent modulator novobiocin in combination fith high dose chemotherapy for the treatment of advanced breast cancer. Biol Blood Marrow Transplant 2000;6(3A):335-43.

Armstrong DK, Davidson NE: Dose intensity for breast cancer. (In press, 2000).





Project 6





T.-C. Wu

Debbie Armstrong

Maura Gillison

Martin Pomper

Chien-Fu Hung




Ya-Chea Tsai

Irena Tartokovsky

Caroline Fidyk





Copyright © 2004 The Johns Hopkins University. All rights reserved.